Feider Stephen's Form 4/A amendment
AmendedBeta Bionics, Inc. (BBNX) · filed Jul 2, 2026
- Accession no.
- 0002048588-26-000010
- Filed
- Jul 2, 2026, 6:44 PM ET
- Trade date
- Jun 26-29, 2026
- Filing delay
- 6 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Jun 30, 2026
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $170.4K. It was filed 6 days after the trade.
This amendment replaces 0002048588-26-000009 (filed Jun 30, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Feider StephenCIK 0002048588 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | Common Stock | MOption exerciseAcquired | +5,104 | $5.10 | +$26,030.4 | 171,157 | Direct | |
| Jun 26, 2026 | Common Stock | SSaleDisposed | −5,104 | $17.05F3 | −$87,006.36 | 166,053 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +4,896 | $5.10 | +$24,969.6 | 170,949 | Direct | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −4,896 | $17.03F4 | −$83,380.84 | 166,053 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | Common Stock | MOption exerciseDisposed | −5,104 | $0.00 | $0 | 44,591 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −4,896 | $0.00 | $0 | 39,695 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions.
- F2
Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
- F3
The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.
- F4
The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.
- F5
The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.